Our Global Partner Network for Cross-Border MedTech Submissions

Why a Network, Not a Single Firm

The default consulting model for cross-border medical device regulation is the global firm — one organization with offices in major regulatory jurisdictions, claiming end-to-end coverage of FDA, EU, Korea, Japan, China, and other markets. The model is convenient on the proposal but consistently produces three operational issues.

1. Regional depth varies dramatically across offices. The Seoul office of a global firm often has fewer senior Korean RA practitioners than a focused Korean practice. The Tokyo office often has fewer senior PMDA practitioners. The depth that matters for a difficult submission concentrates in specialist firms; the global firm offers breadth.

2. Coordination costs eat into the value proposition. Global firms run cross-region engagements through internal coordination layers — global program managers, regional team handoffs, internal communications channels — that add cost without adding regulatory value.

3. Loyalty to internal teams overrides loyalty to client outcome. When the best-fit Korean RA practitioner for a specific submission is at a different firm, the global firm typically does not subcontract. The client receives the firm's second-choice resource rather than the best-fit one.

Leanabl chose a different structure. Rather than build (or claim) global offices in every regulatory jurisdiction, we operate as a Korea-led core with a curated network of regional partners. For each region, we have working relationships with focused specialist firms — the firms that the global firms quietly subcontract to when they need depth.

How the Network Operates

The operating principle is simple: for each client engagement, we identify the best-fit team for each region and orchestrate the work as one program.

For a client running a parallel FDA + EU MDR + MFDS submission, this typically looks like:

• Leanabl holds the central program coordination, the technical file architecture, the Korean regulatory workstream, and the client relationship.
• A US partner firm runs the FDA submission specifics — predicate analysis, 510(k) preparation, FDA interaction.
• An EU partner firm runs the EU MDR submission — Notified Body coordination, EU technical file specifics, EUDAMED registration.
• The client team sits in the middle with one consolidated view rather than three separate firms competing for attention.

The partner firms are chosen based on the specific submission characteristics. A complex AI/SaMD submission may go to one US partner; a traditional hardware Class II submission may go to a different one. The fit is per-engagement, not a fixed alignment.

Who's in the Network

A short, illustrative sample of the partner firms we work with (not exhaustive, and specific firms vary by engagement):

• US regulatory specialists — boutique 510(k) and De Novo firms, FDA cybersecurity specialists, FDA AI/ML submission specialists
• EU Notified Body specialists — firms with strong working relationships with specific Notified Bodies (BSI, TÜV, DEKRA, etc.)
• PMDA specialists — Japanese-language native practitioners with PMDA pre-submission meeting experience
• NMPA specialists — Chinese-language native practitioners with NMPA submission and inspection experience
• ANVISA specialists — Brazilian regulatory practitioners for Latin American expansion
• Clinical CROs — region-specific clinical trial coordinators where local data is required

The relationships are working partnerships, not formal alliances. We have not built a federated brand or a co-marketed offering. We coordinate quietly, in service of client outcomes, and present the work as one program to the client.

What This Means for Clients

The client experience is intended to be a single point of accountability with global depth behind it. Specifically:

• One contract, with Leanabl. The partner firms are subcontracted under our master engagement.
• One project plan, integrated across regions. Critical path items are visible, regional milestones are coordinated.
• One technical file architecture, designed once and re-projected into regional formats. The partner firms work from the same shared source.
• One contact for status and escalation. The client does not coordinate between firms.

What the client gets in exchange for the slight margin of coordination overhead is genuine depth in each region. The Korean work is done by a Korean specialist team. The FDA work is done by an FDA specialist team. The same person is not pretending to be expert in both.

Why Korea Sits at the Core

A frequent question: why does Leanabl position Korea at the core of the network rather than as one regional capability among many?

The answer is straightforward. We started as a Korean practice. Our senior team is Korean by experience and language. Korea is where we have the depth and the operational independence to be the program lead. We do not pretend to have equivalent depth in the US or EU; we have partners for that.

This is a deliberate choice. Many consulting firms position themselves as "global," then carry significant blind spots. We have chosen to be honest about where we are deep (Korea, broader Asia-Pacific) and where we work through partners (US, EU, Latin America).

How New Partners Get Added

We are conservative about adding partner firms. New relationships go through:

• Senior practitioner interview (does the firm's senior RA staff match the experience and judgment we expect from our own?)
• Reference engagement (we typically partner on a small joint engagement before committing to larger cross-region work)
• Client outcome validation (we follow up with the partner's clients to verify their work quality)

Most of our partner relationships have existed for 3+ years. We add new firms slowly because the cost of a poor partner is large — the client experience is what suffers.

The Honest Trade-off

A network-based model has trade-offs we acknowledge:

• Less centralized brand consistency. Partner firms have their own brand and culture. The client may interact with multiple firm logos during a cross-region engagement.
• More upfront coordination cost. Setting up a multi-firm engagement takes more discussion than a single-firm proposal.
• Less margin to a single firm. The economics are split across the network rather than captured by one firm.

These trade-offs are intentional. They are the cost of optimizing for client outcome rather than for firm growth.

Where Leanabl Plugs In

Cross-border engagements run through our Submissions practice with regional partner coordination. For Korea-focused work that is the firm's center of gravity, the solutions catalog covers the full Korean medical device regulatory landscape. The Partners page describes the partner network model in more detail.